Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYMR Kymera Therapeutics, Inc.

盘前交易 07-28 05:52:06 EDT

110.05

-0.52

-0.47%

盘前110.40

+0.35+0.32%

04:50 EDT

最高113.00	最低109.93	成交量47.42万
今开110.57	昨收110.57	日振幅2.78%
总市值90.52亿	流通市值69.91亿	总股本8,226万
成交额5,251万	换手率0.75%	流通股本6,353万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":110.05,"timestamp":1785182400000,"preClose":110.57,"halted":0,"volume":474166,"hourTrading":{"tag":"盘前","latestPrice":110.4,"preClose":110.05,"latestTime":"04:50 EDT","volume":2,"amount":220.450012,"timestamp":1785228622171,"change":0.35,"changeRate":0.00318,"amplitude":0.00318},"delay":0,"changeRate":-0.004702903138283404,"floatShares":63525076,"shares":82257588,"eps":-3.545844,"marketStatus":"盘前交易","change":-0.52,"latestTime":"07-28 05:52:06 EDT","open":110.57,"high":113,"low":109.925,"amount":52506338.148109995,"amplitude":0.02781,"askPrice":122.42,"askSize":15,"bidPrice":107.2,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-3.545844,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785245400000},"marketStatusCode":1,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":110.05,"preHourTrading":{"tag":"盘前","latestPrice":110.4,"preClose":110.05,"latestTime":"04:50 EDT","volume":2,"amount":220.450012,"timestamp":1785228622171,"change":0.35,"changeRate":0.00318,"amplitude":0.00318},"postHourTrading":{"tag":"盘后","latestPrice":108,"preClose":110.05,"latestTime":"19:34 EDT","volume":19170,"amount":2104834.1,"timestamp":1785195248462,"change":-2.05,"changeRate":-0.018628,"amplitude":0.018628},"volumeRatio":0.8896459698804274,"impliedVol":0.7051,"impliedVolPercentile":0.592},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"1176205308","title":"RBC将Kymera Therapeutics评级下调至行业表现，目标价上调至115美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176205308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176205308?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:33","pubTimestamp":1783935195,"startTime":"0","endTime":"0","summary":"RBC资本市场调整了对Kymera Therapeutics Inc.的投资评级，将其从“跑赢大盘”下调至“行业表现”。与此同时，该机构将其目标股价从106美元上调至115美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151401569","title":"Kymera Therapeutics任命Elizabeth Laws博士为全球项目团队负责人，负责首创口服Stat6降解剂KT-621的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1151401569","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151401569?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:05","pubTimestamp":1783422350,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics宣布任命Elizabeth Laws博士担任高级副总裁兼全球项目团队负责人，将全面负责公司首创口服Stat6降解剂KT-621的研发项目。此项人事任命旨在加速该创新疗法的临床开发进程。KT-621作为一款具有突破性潜力的候选药物，其研发进展备受业界关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102703936","title":"异动解读｜Kymera Therapeutics盘中下跌7.48%，报107.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102703936","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102703936?lang=zh_cn&edition=full","pubTime":"2026-06-27 01:57","pubTimestamp":1782496658,"startTime":"0","endTime":"0","summary":"6月26日，Kymera Therapeutics盘中下跌7.48%，报107.82美元/股，成交额1.24亿美元。Kymera Therapeutics所在的生物科技行业中，个股中，艾伯维公司涨1.5%，福泰制药涨2.65%，Moderna涨12.43%，吉利德科学涨2.39%，Apogee Therapeutics跌0.04%。Kymera Therapeutics是一家临床阶段生物制药公司，专注于利用人体天然蛋白质降解系统开发新型小分子疗法，拥有专有的Pegasus靶向蛋白质降解平台，核心管线KT-621为首创口服STAT6降解剂，目前正推进针对特应性皮炎及哮喘的2b期临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128024472","title":"Kymera Therapeutics完成湿疹中期试验入组，盘前股价大涨10.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128024472","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128024472?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:55","pubTimestamp":1782388515,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其针对湿疹的中期临床试验已完成患者入组工作。受此消息提振，该公司股价在盘前交易时段大幅上涨10.2%。\n这一进展标志着该公司主要研发项目中的一个重要里程碑，为后续的数据分析和临床结果评估铺平了道路。市场对这项试验的潜在积极成果抱有期待，从而推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190555506","title":"Kymera Therapeutics完成KT-621治疗特应性皮炎2B期Broaden2试验患者入组，关键数据预计2026年底公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1190555506","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190555506?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:02","pubTimestamp":1782385353,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 已顺利完成其候选药物KT-621用于治疗特应性皮炎的2B期Broaden2临床试验的患者入组工作。该试验的关键顶线数据预计将于2026年底前揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138193718","title":"Kymera Therapeutics宣布口服Irak4降解剂KT-485一期试验首例受试者给药，并达成与赛诺菲合作里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1138193718","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138193718?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:01","pubTimestamp":1781002892,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其口服Irak4降解剂KT-485的一期临床试验已完成首例受试者给药。同时，该公司也确认已根据与赛诺菲（Sanofi）的合作协议，实现了一项重要的里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134368601","title":"Kymera Therapeutics 宣布在皮肤病研究学会和美国胸科学会大会上展示其首创口服Stat6降解剂KT-621","url":"https://stock-news.laohu8.com/highlight/detail?id=1134368601","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134368601?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:01","pubTimestamp":1778842895,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 宣布，其首创的口服STAT6降解剂KT-621的研究成果，将在即将举行的皮肤病研究学会和美国胸科学会国际大会上进行展示。该药物KT-621是一种旨在选择性降解STAT6蛋白的新型口服疗法。在SID和ATS这两个重要的学术会议上展示数据，意味着KT-621在皮肤病学和呼吸病学两个关键治疗领域均获得了研究进展的认可。对于Kymera公司而言，在权威学术会议上公布其领先项目的积极数据，是推动管线发展、增强投资者信心的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138387402","title":"Kymera Therapeutics公司KT-621治疗特应性皮炎的BROADEN2二期B阶段试验进行中，数据预计2027年中公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1138387402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138387402?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078205,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其重点候选药物KT-621针对中重度特应性皮炎的BROADEN2二期B阶段临床试验目前正在顺利推进中。该项关键研究旨在进一步评估该疗法的有效性与安全性。\n根据公司公布的时间表，这项试验的顶线数据结果预计将在2027年中期获得。数据的公布将成为验证KT-621临床潜力的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144121811","title":"Kymera Therapeutics获美国FDA授予KT-621快速通道资格，该口服Stat6降解剂为治疗中重度哮喘的首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1144121811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144121811?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078199,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（简称Kymera Therapeutics）宣布，其首创口服Stat6降解剂KT-621获得美国食品药品监督管理局（FDA）的快速通道资格，用于治疗中重度哮喘患者。这一重要进展有望加速该创新疗法的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108680007","title":"Kymera Therapeutics宣布吉利德科学行使选择权，获得口服Cdk2分子胶降解剂候选药物KT-200授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1108680007","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108680007?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:02","pubTimestamp":1775732525,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics, Inc.今日宣布，其合作伙伴吉利德科学已正式行使选择权，获得口服Cdk2分子胶降解剂开发候选药物KT-200的授权许可。这一决定标志着双方在创新肿瘤疗法合作中的重要里程碑。通过分子胶降解技术，KT-200旨在高效降解致病蛋白，为肿瘤治疗提供新机制。此次选择权的行使，不仅验证了Kymera Therapeutics在蛋白质降解领域的研发实力，也为吉利德科学扩充其肿瘤管线增添了重要资产。双方将继续推进该候选药物的后续开发工作，加速其向临床应用的转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115634896","title":"Kymera Therapeutics公布KT-621一期B组数据，将在美国皮肤病学会年会进行重磅口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1115634896","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115634896?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:02","pubTimestamp":1773140575,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics公司宣布，其研发的KT-621一期B组临床试验数据被选为美国皮肤病学会（AAD）年会上的重磅口头报告环节。这一突破性进展凸显了该疗法在皮肤病领域的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104281611","title":"异动解读 | 强劲财报与充足现金储备提振信心，Kymera Therapeutics盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104281611","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104281611?lang=zh_cn&edition=full","pubTime":"2026-02-27 04:55","pubTimestamp":1772139313,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（KYMR）今日盘中股价大幅上涨5.04%，市场表现活跃。消息面上，公司于盘前正式公布了2025年第四季度及全年财务业绩，并同步更新了业务进展。报告显示，公司财务状况稳健，截至2025年12月31日，持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障，预计足以支持公司各项业务推进至2029年。强劲的财务表现和充裕的现金状况，有效增强了投资者对公司长期发展潜力的信心，从而推动了股价在交易时段的显著上扬。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171937452","title":"异动解读 | 股东拟出售3139万股，Kymera Therapeutics盘前大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171937452","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171937452?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:28","pubTimestamp":1772112516,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics, Inc.今日盘前股价大幅下挫7.88%，引起了市场的广泛关注。消息面上，根据美国证券交易委员会披露的文件显示，Kymera Therapeutics的部分现有股东计划出售总计3139万股公司普通股。此类由股东发起的售股行为将增加市场中的股票供应量，通常被视为潜在的利空信号，可能引发投资者对公司股票未来走势的担忧，从而导致股价承压下跌。需要指出的是，此次售股由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155188159","title":"Kymera Therapeutics公司 - 股东拟出售3139万股普通股 - 美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155188159","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155188159?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:27","pubTimestamp":1772112453,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，生物技术公司Kymera Therapeutics, Inc. 的部分现有股东计划出售总计3139万股公司普通股。\n此次售股行为由公司股东发起，而非公司发行新股，因此Kymera Therapeutics公司自身不会从此次售股中获得任何收益。此类股东减持行为通常会引起市场对公司股票未来供应量及股价潜在波动的关注。投资者需密切关注后续市场动态及相关公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131455532","title":"Kymera Therapeutics, Inc. 财务状况稳健：截至2025年12月31日持有16亿美元现金，资金可支撑至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1131455532","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131455532?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:18","pubTimestamp":1772108303,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. 展现出强劲的财务实力。截至2025年12月31日，公司持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障，预计足以支持公司各项业务推进至2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146980037","title":"Kymera Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1146980037","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146980037?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:13","pubTimestamp":1772108026,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.（简称\"Kymera Therapeutics\"）近日正式披露了其2025年第四季度及全年的财务报告，同时向市场通报了公司最新的业务动态。此次公布涵盖了公司在关键财务指标上的表现，以及研发管线、战略合作等方面的进展，为投资者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143087468","title":"Kymera Therapeutics宣布首例患者完成KT-621给药——首创口服Stat6降解剂进入Breadth二期B阶段哮喘临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1143087468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143087468?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:01","pubTimestamp":1769688060,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics宣布，其创新药物KT-621已完成针对哮喘患者的首例给药，标志着该口服Stat6降解剂正式进入Breadth二期B阶段临床试验。作为同类首创疗法，KT-621通过靶向降解Stat6蛋白来调节免疫反应，为中重度哮喘患者提供潜在治疗选择。此次临床试验旨在评估KT-621的安全性、耐受性及有效性，预计将纳入多国临床研究中心的重症哮喘患者。该阶段试验数据的收集与分析，将为后续全球临床开发策略提供关键依据。Stat6信号通路在过敏性炎症疾病中扮演核心角色。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517437281","title":"Kymera Therapeutics, Inc.2024财年实现净利润-2.24亿美元，同比减少52.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517437281?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日，Kymera Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.24亿美元，同比减少52.38%；其中营业收入为47.07百万美元，同比减少40.11%，每股基本收益为-2.98美元。从资产负债表来看，Kymera Therapeutics, Inc.总负债1.42亿美元，其中短期债务13.11百万美元，资产负债比为6.89，流动比率为0.08。机构评级：截至2025年3月8日，当前有17家机构对Kymera Therapeutics, Inc.目标价做出预测，其中目标均价为58.82美元，其中最低目标价为41.00美元，最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000043abed65dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYMR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147904941","title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147904941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147904941?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:10","pubTimestamp":1740669010,"startTime":"0","endTime":"0","summary":"生物技术公司Kymera Therapeutics今日盘中股价大幅下跌7.27%,引发市场广泛关注。据统计,截至收盘KYMR报33.34美元,成交量3.18万股,振幅4.84%。公司最新公布的2024年第四季度财报显示,KYMR当季每股亏损0.88美元,远高于华尔街分析师预期的0.78美元亏损。与去年同期相比,营收更是大幅下滑84.56%。显而易见,Kymera Therapeutics业绩大幅逊于市场预期,给投资者带来了较大的不确定性和失望。公司财务数据的疲软表现,可能是导致KYMR股价今日大跌的主要诱因之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Kymera Therapeutics第四季度业绩逊预期 盘中股价大跌7.27%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385542","title":"Kymera Therapeutics, Inc.盘中异动 早盘大幅跳水5.71%报33.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385542?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:40","pubTimestamp":1740667238,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时40分，Kymera Therapeutics, Inc.股票出现异动，股价大幅下跌5.71%。Kymera Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。Kymera Therapeutics, Inc.公司简介：Kymera Therapeutics Inc是一家生物技术公司，开创了一种变革性的新方法来治疗以前无法治愈的疾病。Kymera的Pegasus靶向蛋白质降解平台利用人体的天然蛋白质回收机制降解致病蛋白质，重点关注常规药物目前无法通过的有效途径中的非药物节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224039a2567cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.3125},{"period":"6month","weight":0.5465},{"period":"1year","weight":1.4034},{"period":"ytd","weight":0.4143}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0139},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.0628},{"period":"1year","weight":0.1601},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kymera Therapeutics, Inc.是一家有限责任公司，于2017年5月25日根据特拉华州法律成立。该公司是一家生物制药公司，专注于发现和开发新型小分子疗法，利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白。该公司拥有专有的靶向蛋白质降解平台，名为Pegasus，能够发现对全身致病蛋白具有强效活性的高选择性小分子蛋白质降解剂。该公司认为，其小分子蛋白质降解剂相比现有疗法具有显著优势，能够针对此前传统疗法难以触及的人类基因组的大部分区域进行治疗。该公司专注于已通过临床验证但关键生物节点/蛋白质尚未被药物靶向或药物靶向效果不佳的生物通路。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.014692},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.075866},{"month":4,"riseRate":0.5,"avgChangeRate":0.006528},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.121889},{"month":6,"riseRate":0.666667,"avgChangeRate":0.163264},{"month":7,"riseRate":0.666667,"avgChangeRate":0.136893},{"month":8,"riseRate":0.6,"avgChangeRate":0.035263},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069597},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kymera Therapeutics, Inc.(KYMR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}